- Home
- GGT vs EDIT Comparison
GGT vs EDIT Comparison
Compare GGT & EDIT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GGT | EDIT |
|---|---|---|
| Founded | 1994 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Trusts Except Educational Religious and Charitable | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 144.8M | 233.3M |
| IPO Year | N/A | 2016 |
Fundamental Metrics
Financial Performance| Metric | GGT | EDIT |
|---|---|---|
| Price | $4.18 | $2.55 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 10 |
| Target Price | N/A | ★ $4.13 |
| AVG Volume (30 Days) | 59.7K | ★ 1.5M |
| Earning Date | 01-01-0001 | 11-10-2025 |
| Dividend Yield | ★ 15.56% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | N/A | ★ $46,383,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $6.90 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $4.32 | $0.91 |
| 52 Week High | $7.00 | $4.54 |
Technical Indicators
Market Signals| Indicator | GGT | EDIT |
|---|---|---|
| Relative Strength Index (RSI) | 55.69 | 48.30 |
| Support Level | $4.16 | $2.09 |
| Resistance Level | $4.32 | $2.70 |
| Average True Range (ATR) | 0.05 | 0.16 |
| MACD | 0.02 | 0.06 |
| Stochastic Oscillator | 59.09 | 75.41 |
Price Performance
Historical ComparisonAbout GGT Gabelli Multi-Media Trust Inc. (The)
Gabelli Multimedia Trust Inc is a non-diversified closed-end management investment company. Its investment objective is the long-term growth of capital with income as a secondary objective. The fund invests majority of its assets, under normal market conditions, in common stock and other securities, including convertible securities, preferred stock, options, and warrants of companies in the telecommunications, media, publishing, and entertainment industries.
About EDIT Editas Medicine Inc.
Editas Medicine Inc is a clinical-stage genome editing company dedicated to developing potentially transformative genomic medicines to treat a broad range of serious diseases. The company focuses on developing a proprietary genome editing platform based on clustered, regularly interspaced short palindromic repeats (CRISPR)/ CRISPR-associated protein 9 (Cas9 technology). It has developed CRISPR/Cas9 technology which uses a protein-RNA (ribonucleic acid) complex composed of the Cas9 enzyme bound to a guide RNA molecule designed to recognize a DNA (deoxyribonucleic acid) sequence that requires repair. The company is engaged in developing and commercializing genome editing technology.